ALCHEMIST

Bringing genomic discovery and targeted therapies to early-stage lung cancer

D. E. Gerber, G. R. Oxnard, R. Govindan

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.

Original languageEnglish (US)
Pages (from-to)447-450
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume97
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Lung Neoplasms
National Cancer Institute (U.S.)
Epidermal Growth Factor Receptor
Therapeutics
Mutation
Neoplasms
anaplastic lymphoma kinase

ASJC Scopus subject areas

  • Medicine(all)

Cite this

ALCHEMIST : Bringing genomic discovery and targeted therapies to early-stage lung cancer. / Gerber, D. E.; Oxnard, G. R.; Govindan, R.

In: Clinical Pharmacology and Therapeutics, Vol. 97, No. 5, 01.05.2015, p. 447-450.

Research output: Contribution to journalArticle

@article{dee2676791614e16a33e7b1998204942,
title = "ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer",
abstract = "The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.",
author = "Gerber, {D. E.} and Oxnard, {G. R.} and R. Govindan",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/cpt.91",
language = "English (US)",
volume = "97",
pages = "447--450",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - ALCHEMIST

T2 - Bringing genomic discovery and targeted therapies to early-stage lung cancer

AU - Gerber, D. E.

AU - Oxnard, G. R.

AU - Govindan, R.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.

AB - The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.

UR - http://www.scopus.com/inward/record.url?scp=84932126124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932126124&partnerID=8YFLogxK

U2 - 10.1002/cpt.91

DO - 10.1002/cpt.91

M3 - Article

VL - 97

SP - 447

EP - 450

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -